- Home
- BTBT vs XFOR Comparison
BTBT vs XFOR Comparison
Compare BTBT & XFOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BTBT | XFOR |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.6M | 377.3M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BTBT | XFOR |
|---|---|---|
| Price | $1.63 | $2.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $4.10 | ★ $11.60 |
| AVG Volume (30 Days) | ★ 24.8M | 1.1M |
| Earning Date | 11-13-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $113,560,320.00 | $6,500,000.00 |
| Revenue This Year | $32.29 | N/A |
| Revenue Next Year | $109.11 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 5.10 | ★ 150.00 |
| 52 Week Low | $1.18 | $2.80 |
| 52 Week High | $4.55 | $4.83 |
Technical Indicators
Market Signals| Indicator | BTBT | XFOR |
|---|---|---|
| Relative Strength Index (RSI) | 49.71 | 24.87 |
| Support Level | $1.60 | $2.83 |
| Resistance Level | $1.75 | $4.45 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 44.70 | 8.88 |
Price Performance
Historical ComparisonAbout BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.